The Chilean AIDS Cohort: A model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country - Organization and preliminary results

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 5, 2005, Pages 551-557

  Wolff, Marcelo J ^a,c   Beltrán, Carlos J ^a   Vásquez, Patricia ^a   Ayala, Marisol X ^a   Valenzuela, Miguel ^a   Berríos, Gloria ^b   Arredondo, Anabella ^b  

^a Chilean AIDS Group   (Chile)

^b National AIDS Commission   (Chile)

^c NONE   (Chile)

Author keywords

Antiretroviral therapy; Cohort studies; Expanded access to therapy; Impact evaluation; Resource limited countries

Indexed keywords

ABACAVIR; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD TOXICITY; CHILE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG WITHDRAWAL; EVALUATION; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERSENSITIVITY; INCOME; INTERNET; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; TOXICITY; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CHILE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NATIONAL HEALTH PROGRAMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGRAM EVALUATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 27944484854     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000185573.98472.f8     Document Type: Article

References (21)

1. World Health Organization. Global Summary of the AIDS Epidemic. Geneva: World Health Organization; 2005. Available at: http://www. unaids.org/wad2004/ EPI_1204_pdf_en/Chapter0-1_intro_en.pdf.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Messeri P, Lee G, Abramson DM, et al. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care. 2003;41:512-521.
4. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
5. Egger M, May M, Chene G, et al. ART Cohort Collaboration prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
6. World Health Organization. Treat 3 Million by 2005 (3 by 5) Initiative. Geneva: World Health Organization; 2004. Available at: http://www. unaids.org/en/treat+3+million+by+2005+initiative.asp.
7. Brazilian Ministry of Health. The impact of antiretroviral therapy. Secretariat for Special Health Projects. National coordination for DST/AIDS, July 17, 2004. Available at: http://www.aids.gov.br/antiretrov_therap.htm.
8. Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Cote d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS. 2003; 17(Suppl 3):S1-S4.
9. Comisión Nacional de SIDA. Caracterización epidemiológica de la infección por VIH/SIDA en Chile: Diciembre de 2003. Rev Chil Infectol. 2005;22:169-202.
10. Comisión Nacional del SIDA. Guía Clínica para la Atención de las Personas Adultas que viven con VIH/SIDA. Gobierno de Chile, Ministerio de Salud, Octubre 2001.
11. Wolff M, Beltrán C, Gallardo D, et al, for the ChiAC Group and CONASIDA. A national antiretroviral therapy expanded-access-program and the Chilean AIDS cohort: a model for ART in a middle-income country. Presented at: 43th ICAAC Conference; 2003; Chicago.
12. Vasquez P, Beltrán C, Gallardo D, et al, for the Chilean AIDS Study Group, CONASIDA. Efficacy of HAART in patients with extremely advanced HIV disease in a middle income country. Chilean AIDS Cohort. Presented at: Ninth European Congreso Europeo on AIDS; 2003; Warsaw.
13. Beltrán C, Wolff M, Morales R, et al, for the Chilean AIDS Cohort and CONASIDA. A national cohort model for assessing the effect of an expanded program to antiretroviral therapy and the short-term predictors for efficacy in a middle-income country. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
14. Petoumenos K. Australian HIV observational database. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database. J Clin Virol. 2003;26:209-222.
15. Perez-Hoyos S, del Amo J, Muga R, et al. GEMES (Spanish Multicenter Study Group of Seroconverters). Effectiveness of highly active anti-retroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS. 2003;17:353-359.
16. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Results from the EuroSIDA Study. Arch Intern Med. 2000;160:1123-1132.
17. Lundgren J, Mocroft A, Gatell J, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study. J Infect Dis. 2002;185:178-187.
18. MacArthur RD, Perez G, Walsmley S, et al. CD4+ cell count is a better predictor of disease progression than HIV RNA level in persons with advanced HIV infection on highly active antiretroviral therapy [abstract 203]. Presented at: Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago.
19. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA Study. Ann Intern Med. 1999;130:570-577.
20. Ministry of Health, Chile. Clinical Guidelines: Acquired Immunodeficiency Syndrome. Santiago: Ministry of Health; 2005.
21. Reynolds SJ, Bartlett JG, Quinn TC, et al. Antiretroviral therapy where resources are limited. N Engl J Med. 2003;348:1806-1809.